Completed PHASE4 INTERVENTIONAL 2-arm NCT01585038

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

A Randomized Controlled Trial Comparing Efavirenz With Rilpivirine on Changes in Endothelial Function, Inflammatory Markers, and Oxidative Stress in HIV-uninfected Healthy Volunteers

Sponsor: Indiana University

Conditions Cardiovascular Disease

Interventions Efavirenz Rilpivirine

Updated 5 times since 2017 Last updated: Jul 27, 2015 Started: Jul 31, 2012 Primary completion: May 31, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Cardiovascular Disease and is currently completed. Indiana University leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University
Janssen Services, LLC

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States